Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.00599/full |
id |
doaj-fed946e84bb344aeb330b1204514f125 |
---|---|
record_format |
Article |
spelling |
doaj-fed946e84bb344aeb330b1204514f1252020-11-25T03:32:36ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-09-011110.3389/fendo.2020.00599546946Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective AnalysisSoo Young Kim0Seok-Mo Kim1Jun Won Kim2Ik Jae Lee3Tae Joo Jeon4Hojin Chang5Bup-Woo Kim6Yong Sang Lee7Hang-Seok Chang8Cheong Soo Park9Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Radiation and Oncology, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Radiation and Oncology, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Nuclear Medicine, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaDepartment of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaBackground: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies.Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging.Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64–839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9–10%. The other 16 patients (88.9%) had tumor volume reductions of 2–69%. Six patients (33.3%) had tumor volume reductions ≥50%.Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted.https://www.frontiersin.org/article/10.3389/fendo.2020.00599/fulllenvatinibthyroid carcinomaanaplastic thyroid cancerretrospective studytyrosine kinase inhibitor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Soo Young Kim Seok-Mo Kim Jun Won Kim Ik Jae Lee Tae Joo Jeon Hojin Chang Bup-Woo Kim Yong Sang Lee Hang-Seok Chang Cheong Soo Park |
spellingShingle |
Soo Young Kim Seok-Mo Kim Jun Won Kim Ik Jae Lee Tae Joo Jeon Hojin Chang Bup-Woo Kim Yong Sang Lee Hang-Seok Chang Cheong Soo Park Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis Frontiers in Endocrinology lenvatinib thyroid carcinoma anaplastic thyroid cancer retrospective study tyrosine kinase inhibitor |
author_facet |
Soo Young Kim Seok-Mo Kim Jun Won Kim Ik Jae Lee Tae Joo Jeon Hojin Chang Bup-Woo Kim Yong Sang Lee Hang-Seok Chang Cheong Soo Park |
author_sort |
Soo Young Kim |
title |
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis |
title_short |
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis |
title_full |
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis |
title_fullStr |
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis |
title_full_unstemmed |
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis |
title_sort |
survival with lenvatinib for the treatment of progressive anaplastic thyroid cancer: a single-center, retrospective analysis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2020-09-01 |
description |
Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies.Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging.Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64–839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9–10%. The other 16 patients (88.9%) had tumor volume reductions of 2–69%. Six patients (33.3%) had tumor volume reductions ≥50%.Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted. |
topic |
lenvatinib thyroid carcinoma anaplastic thyroid cancer retrospective study tyrosine kinase inhibitor |
url |
https://www.frontiersin.org/article/10.3389/fendo.2020.00599/full |
work_keys_str_mv |
AT sooyoungkim survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT seokmokim survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT junwonkim survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT ikjaelee survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT taejoojeon survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT hojinchang survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT bupwookim survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT yongsanglee survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT hangseokchang survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis AT cheongsoopark survivalwithlenvatinibforthetreatmentofprogressiveanaplasticthyroidcancerasinglecenterretrospectiveanalysis |
_version_ |
1724567264585318400 |